The STAMP inhibitor asciminib is a new treatment option for ABL-rearranged ALL revealing a novel role for the 5' fusion partner in determining drug response
Laura N Eadie, Daniel P. McDougal, Elias Lagonik, Caitlin E Schutz, Tace S Conlin, Elyse C. Page, Jacqueline A. Rehn, John B. Bruning, Andrew S. Moore, David T. O. Yeung, Timothy P. Hughes, Deborah L. White
This study shows asciminib effectively treats NUP214::ABL1 ALL in preclinical models by inhibiting ABL1 kinase and improving survival.
bioRxiv · May 6, 2025 · PreprintCancer Biology